{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T02:33:15Z","timestamp":1792549995005,"version":"4.5.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012093","name":"Valle de Hebr\u00f3n Instituto de Investigaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012093","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.esmoop.2026.107694","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:07:57Z","timestamp":1777594077000},"page":"107694","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of treatment discontinuation among patients with microsatellite instability or mismatch repair-deficient metastatic colorectal cancer treated with immune checkpoint inhibitors"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8137-5415","authenticated-orcid":false,"given":"J.","family":"Ros","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5480-7045","authenticated-orcid":false,"given":"M.C.","family":"de Grandis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3500-9641","authenticated-orcid":false,"given":"I.","family":"Baraibar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Salva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5023-3521","authenticated-orcid":false,"given":"C.","family":"Vaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Alcaraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Salv\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Mulet-Margalef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8987-4577","authenticated-orcid":false,"given":"J.L.","family":"Manzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5174-4081","authenticated-orcid":false,"given":"R.","family":"Querol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Pampols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Vivancos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2495-8139","authenticated-orcid":false,"given":"J.","family":"Tabernero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4653-6324","authenticated-orcid":false,"given":"E.","family":"Elez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.esmoop.2026.107694_bib1","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107694_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair\u2013deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.107694_bib3","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41575-019-0126-x","article-title":"Immunotherapy in colorectal cancer: rationale, challenges and potential","volume":"16","author":"Ganesh","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.esmoop.2026.107694_bib4","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1001\/jamaoncol.2020.1046","article-title":"Outcomes following immune checkpoint inhibitor treatment of patients with microsatellite instability-high cancers: a systematic review and meta-analysis","volume":"6","author":"Petrelli","year":"2020","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2026.107694_bib5","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","article-title":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study","volume":"23","author":"Diaz","year":"2022","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.107694_bib6","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.dld.2020.11.031","article-title":"Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: the SAMCO-PRODIGE 54 randomised phase II trial","volume":"53","author":"Ta\u00efeb","year":"2021","journal-title":"Dig Liver Dis"},{"issue":"suppl 5","key":"10.1016\/j.esmoop.2026.107694_bib7","doi-asserted-by":"crossref","first-page":"V128","DOI":"10.1093\/annonc\/mdx367.020","article-title":"Efficacy of pembrolizumab in phase 2 KEYNOTE-164 and KEYNOTE-158 studies of microsatellite instability high cancers","volume":"28","author":"Diaz","year":"2017","journal-title":"Ann Oncol"},{"issue":"suppl 2","key":"10.1016\/j.esmoop.2026.107694_bib8","doi-asserted-by":"crossref","first-page":"S1271","DOI":"10.1016\/j.annonc.2023.10.024","article-title":"LBA32 Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)\/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the randomized phase III KEYNOTE-177 study","volume":"34","author":"Shiu","year":"2023","journal-title":"Ann Oncol"},{"issue":"3 suppl","key":"10.1016\/j.esmoop.2026.107694_bib9","article-title":"Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high\/mismatch repair-deficient (MSI-H\/dMMR) metastatic colorectal cancer (mCRC): first results of the CheckMate 8HW study","volume":"42","author":"Andre","year":"2024","journal-title":"J Clin Oncol"},{"issue":"suppl 2","key":"10.1016\/j.esmoop.2026.107694_bib10","doi-asserted-by":"crossref","first-page":"S453","DOI":"10.1016\/j.annonc.2024.08.613","article-title":"544P Nivolumab plus ipilimumab in microsatellite instability high (MSI)\/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): final survival analysis and prognostic evaluation of GDF-15 in the phase II GERCOR NIPICOL study","volume":"35","author":"Depotte","year":"2024","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.esmoop.2026.107694_bib11","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability\u2013high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.esmoop.2026.107694_bib12","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa2402141","article-title":"Nivolumab plus ipilimumab in microsatellite-instability-high metastatic colorectal cancer","volume":"391","author":"Andre","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107694_bib13","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.esmoop.2026.107694_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114336","article-title":"Duration of immunotherapy in dMMR\/MSI-H metastatic colorectal cancer patients","volume":"212","author":"Margalit","year":"2024","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107694_bib15","first-page":"32","article-title":"Clinical outcomes of elective early discontinuation of immunotherapy based on objective response in microsatellite instability-high metastatic colorectal cancer","volume":"24","author":"Xiao","year":"2025","journal-title":"Clin Colorectal Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2026.107694_bib16","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/jnci\/djaa052","article-title":"Pathological tumor response following immune checkpoint blockade for deficient mismatch repair advanced colorectal cancer","volume":"113","author":"Ludford","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.esmoop.2026.107694_bib17","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1158\/2767-9764.CRC-23-0340","article-title":"Sustained disease control in immune checkpoint blockade responders with microsatellite instability-high colorectal cancer after treatment termination","volume":"3","author":"Simmons","year":"2023","journal-title":"Cancer Res Commun"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107694_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010424","article-title":"Early treatment discontinuation in patients with deficient mismatch repair or microsatellite instability high metastatic colorectal cancer receiving immune checkpoint inhibitors","volume":"13","author":"Taieb","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"9","key":"10.1016\/j.esmoop.2026.107694_bib19","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1158\/1078-0432.CCR-20-3677","article-title":"Combined analysis of concordance between liquid and tumor tissue biopsies for RAS mutations in colorectal cancer with a single metastasis site: the METABEAM study","volume":"27","author":"Kagawa","year":"2021","journal-title":"Clin Cancer Res"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926016364?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926016364?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T05:13:09Z","timestamp":1780290789000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926016364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2059702926016364"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.107694","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of treatment discontinuation among patients with microsatellite instability or mismatch repair-deficient metastatic colorectal cancer treated with immune checkpoint inhibitors","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.107694","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"107694"}}